Research & Development
Unleash the power of data driven trials. Elevate research with our digital trial companions.
Clinical trials
Advancement in quality of treatment
Development in individual health behaviour of patients
Improvement in efficiency of the entire therapy
The potential of data unlocks new insights in dermatology
Our versatile technology plays a pivotal role in clinical trials by collecting comprehensive data on various factors such as lifestyle, environmental exposures, medication use, and patient-reported outcomes. By integrating advanced technologies like wearables, machine vision, and remote patient monitoring, we can develop customized digital study companions tailored to the specific requirements of each trial. This flexible approach enables researchers to analyze complex datasets precisely while enhancing participant compliance through motivating interactions, ultimately contributing to the development of more effective treatments.
Explore the detailed overview of our clinical trial studies, showcasing how our digital health platform can deliver precise insights and enhance research methodologies.
Within the NICE study, subjects with atopic dermatitis and acute eczema on both arms participated for six weeks. One arm received a lotion with active components, the other a placebo, applied twice daily. Bi-weekly examinations included skin assessments and microbiome swabs and a daily symptom diary was maintained. The study evaluated the lotion’s effectiveness in stabilizing the skin barrier, improving SCORAD scores, extending remission, and analyzing microbiome changes.
In cooperation with:
The study aimed to evaluate the effectiveness of an app-based patient educational and clinical assessment. Adult patients suffering of atopic dermatitis with a significant impact on quality of life due to their disease were recruited.
Participants were randomly assigned to either an app group or a control group. Those in the app group regularly accessed educational material and documented disease activity in the “Nia” app alongside standard care, which included corticosteroid and emollient therapy.
The primary goal was to measure changes in quality of life from the beginning to the end of the 12-week period. Disease severity and related symptoms were evaluated before, midway through, and at the end of the digital intervention.
In cooperation with:
The ProRaD study is a multicenter observational study and aims to develop new prevention and treatment strategies to enhance our understanding of the mechanisms affecting atopic dermatitis and related allergic conditions.
Participants regularly complete detailed questionnaires, and biomaterials such as blood, tissue, and skin swabs are collected for analysis. The insights gained will support the development of innovative approaches to manage these conditions.
In cooperation with:
The ADCompanion study includes 600 participants of varying ages, divided into two groups: one receiving standard care with optional in-person training, and the other supplemented with the app’s digital resources.
Our study app offers certified training content, tools for tracking symptoms, triggers, and treatments as well as video consultations. Participants can book video consultations with experts via our study app, focusing on nutrition, care, and psychosocial support.
The study investigates if digital interventions and video consultations are as effective as traditional care, with an additional focus on quality of life, itch intensity, and psychological stress.
In cooperation with:
Our KI-AD study leverages AI, specifically machine vision, to streamline the collection of clinical scores in dermatology, addressing the challenges of manual scoring. By analyzing clinical images, our AI aims to provide faster, more accurate, standardized, and cost-effective assessments.
Participants with atopic dermatitis are involved in taking photographs of lesional and non-lesional skin using a smartphone and the Nia app. Images can be captured by patients at home or by doctors in clinics, and are subsequently segmented and classified to “train” the AI system for improved analysis and scoring.
In cooperation with:
This study explores the factors influencing treatment adherence in patients with moderate to severe atopic dermatitis. Conducted as a prospective, multicenter, open-label, single-arm, non-interventional study, dermatologists from the German Dermatologists Association (BVDD) can enroll up to 10 patients each. Over an observation period of up to 12 months and four visits, the primary focus is to descriptively analyze treatment satisfaction and adherence using the “Atopic Dermatitis Control Tool” (ADCT) and “Neurodermatitis Evaluation Test Tool” (NETT). Additionally, the study examines the quality of life of these patients and the effect of the Nia App on doctor-patient interactions, utilizing routine care data, patient questionnaires, and Nia App data.
In cooperation with:
Our Psoriasis AI study utilizes cutting-edge AI, specifically machine vision, to enhance the collection and evaluation of clinical scores in dermatology, addressing the inefficiencies of manual processes. Through the analysis of clinical images, our AI aims to offer assessments that are faster, more accurate, standardized, and cost-effective.
Participants with psoriasis will use the Sorea app on their smartphones to take photographs of both affected and unaffected skin areas. These images can be captured by patients at home or by healthcare professionals in clinical environments. The AI system segments and classifies these images to “train” itself, thereby improving its analysis and scoring capabilities for more precise psoriasis management.
In cooperation with:
Scientific publications
- Alneebari R., Digitale Unterstützungsoptionen für die Behandlung, Dermatologie Praxis, Ausgabe 3, Juni 2021, S. 10-11
- Globig, P. (2023, October 11-14), Impact of a digital application on the quality of life of patients with atopic dermatitis [Poster presentation 1911], EADV Congress Berlin, Germany
The study evaluated the effectiveness of an app-based educational and clinical assessment tool for adults with atopic dermatitis impacting their quality of life. Participants were randomly assigned to an app group, accessing educational material and documenting disease activity in the “Nia” app alongside standard care, or a control group receiving only standard care. The primary focus was on measuring changes in quality of life over 12 weeks, with disease severity and symptoms assessed at multiple intervals.
Full publication here
- Matusiewicz D., Digital Health in 2023: Uns erwartet ein spannendes Jahr!. Kompass Dermatol 2023;11:36-45, S. 41. doi: 10.1159/000529373
Patient empowerment and increased adherence. Nia Health bridges the gap between medical care and patients.
The aim is to provide comprehensive digital support to enable people with chronic skin conditions to receive optimal therapy support in the long term. The award-winning ‘Nia’ atopic dermatitis app, the first digital medical device to be approved, has been offering patients clinically validated support in their everyday lives since 2019, complementing traditional treatment.
Full publication here
- Schuster B., Dugas M., Zink A., Medizinische Apps–Möglichkeiten bei Pruritus, Der Hautarzt; 2020. p. 1.
Apps are becoming an increasingly common part of our lives. They could also play a role in the treatment of pruritus. The aim of this article is to provide an overview of apps for pruritus that are already available. It also aims to show whether and how the identified pruritus apps have been validated and what features may still be lacking.
Full Publication here
- Staab D., Digitale Ergänzung zu bestehenden Schulungsangeboten für Neurodermitiker, Allergo Journal Int 2020; 29: 199-266
- Telschow, J., Hamelmann, E., Neustädter, I. et al. Interdisziplinäre und digitale Versorgung von Kindern und Jugendlichen mit chronischen Erkrankungen. Monatsschr Kinderheilkd 173, 637–645 (2025).
Atopic dermatitis is the most common chronic skin condition in children, severely impacting the quality of life of affected families. Standardized educational programs for children, teenagers, and parents have been proven to positively affect disease severity, itching, sleep, quality of life, and self-efficacy. However, in-person training is not widely accessible across all regions of Germany. Digital formats could address this gap and have shown success in other countries. Currently, studies in Germany like AD-Companion are evaluating the effectiveness of digital training programs to provide interdisciplinary care, even in underserved areas.
Full publication here
- Telschow, J., Abraham, S., Cornelius, A. (2024) Charakteristika, Versorgungslage und Erwartungshaltung von Menschen mit atopischer Dermatitis im Rahmen der ADCompanion Studie zur Evaluation einer digitalen Versorgungsform für strukturschwache Regionen [Poster A-248], 19. Deutscher Allergiekongress, Dresden, Germany
People with atopic dermatitis (AD) often suffer from significant limitations in their quality of life. Age-appropriate training courses are effective, but not widely available. ADCompanion is a service offering digitised training content, symptom and trigger recording, plus individual video consultations on nutrition, skin care and psychosocial aspects.
Full publication here
- Traidl-Hoffmann C., Digitale Technologien und Polleninformationsnetzwerke: Hilfsmittel für eine patientenorientierte Versorgung bei allergischen Erkrankungen, Kompass Dermatol, November 2021; 9: 194–195
The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users.
Full publication here